NRG Therapeutics Raises £50M Series B for Neurodegenerative Drug Development

NRG Therapeutics, a neuroscience company based in Stevenage, UK, has raised an oversubscribed £50 million ($67 million) Series B funding round led by SV Health Investors’ Dementia Discovery Fund, with participation from investors including the British Business Bank, Novartis Venture Fund, M Ventures, and Parkinson’s UK. The funding will support the advancement of NRG5051, a first-in-class oral small molecule inhibitor targeting the mitochondrial permeability transition pore (mPTP), which is implicated in mitochondrial dysfunction and neurodegeneration in diseases such as Parkinson’s and amyotrophic lateral sclerosis (ALS)/motor neurone disease (MND). NRG5051 has shown strong neuroprotective effects and reduced neuroinflammation in pre-clinical models and is expected to enter first-in-human clinical trials as early as December 2025 or early 2026. The company aims to generate clinical proof of concept in ALS/MND and to conduct additional studies in Parkinson’s patients, while also developing a labeled drug candidate for PET imaging to validate biomarkers for future trials. CEO Neil Miller emphasized the high unmet medical need and the growing prevalence of neurodegenerative disorders, noting the importance of this funding to advance NRG’s pipeline of mitochondrial therapeutics designed to slow or halt disease progression. The company was founded in 2018 with seed funding from Parkinson’s UK and continues to attract interest from major pharmaceutical players and nonprofit organizations.